Keytruda
Merck to Discontinue Anti-TIGIT, Anti-LAG-3 Programs Based on Lackluster Results
The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.
Merck, Moderna Vax Trial Starts Enrolling Lung Cancer Patients at McGill University Health Center
The trials are evaluating an individualized neoantigen vaccine with Keytruda as an adjuvant therapy for non-small cell lung cancer.
Merck Talks Up Pipeline Diversification as Keytruda Sales Still Comprise 45 Percent of Q3 Revenues
Premium
The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in the third quarter.
Merck, Moderna Launch Phase III Trial of Adjuvant V940 in NSCLC After Neoadjuvant Keytruda, Chemo
The partners are also studying their personalized vaccine with Keytruda as an adjuvant NSCLC treatment for those who haven't gotten neoadjuvant therapy.
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
Sep 9, 2024
Apr 25, 2024
Merck's Keytruda Sales Increase 20 Percent in Q1
Nov 14, 2023